Velicept
Therapeutics develops novel compounds for the treatment of urological and gastrointestinal disorders... Read moreVelicept
Therapeutics develops novel compounds for the treatment of urological and gastrointestinal disorders... Read more
News
Nov 27, 2019
The Business Journals: Philadelphia
Velicept Therapeutics: Wayne biopharma firm raises $6M to advance development of drug candidate
Nov 05, 2019
SEC
Velicept Therapeutics: Velicept Therapeutics has raised $6M in a Debt round.
Mar 28, 2019
BioPortfolio
Velicept Therapeutics: Velicept Therapeutics Announces Positive TopLine Phase 2b Results for Solabegron in the Treatment of Overactive Bladder OAB
Mar 19, 2018
PharmiWeb
Velicept Therapeutics: Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB
Oct 06, 2016
PharmaLeaders
Velicept Therapeutics: FDA accepts Velicept's IND to start phase I study for solabegron
Dec 03, 2015
VC News Daily
Velicept Therapeutics: Velicept Therapeutics Pulls In $21M
Dec 03, 2015
MedCity News
Velicept Therapeutics: Velicept nets $21M for overactive bladder drug
Dec 02, 2015
PE Hub Network
Velicept Therapeutics: Velicept scores $21 mln Series B
Velicept Competitors
1
2
3
4
5
6
7
8
9
10